Herantis Pharma Oyj

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

—

Shrs. gr., 5y

26.16%

Rev. gr., 5y

Revenues

Net income

-7m

L+34.04%

CFO

-6m

L-6.84%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.

URL

https://herantis.com/

IPO date

Jun 11, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT